| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e472e52510b9a0150fb8bb983e5c5a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b29a94e5e8b72ad00aae1ae0f4ae567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa3beedeede2916eb8282927a92291f9 |
| publicationDate |
2021-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112639097-A |
| titleOfInvention |
Exon skipping oligomers for muscular dystrophy |
| abstract |
Antisense oligomers complementary to selected target sites in the human dystrophin gene to induce exon 2 skipping are described. In various aspects, antisense oligomers are described according to formula (I): or a pharmaceutically acceptable salt thereof, wherein T, Nu, n and R 100 are as defined herein. |
| priorityDate |
2018-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |